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HF. According to these recommendations, the diagnosis 
is based on clinical parameters and other laboratory 
tests to determine the etiology and degree of  functional 
impairment. As an example, the task force of  The 
European Society of  Cardiology for the diagnosis and 
treatment of  acute congestive HF (CHF) recommended 
that a cardiac natriuretic hormone (brain natriuretic peptide 
[BNP]) assay should be included as a first step of  in the 
diagnosis of  HF along with electrocardiography (ECG) and 
chest X-rays. Missov et al.,1 Missov and Mair2 first reported 
the association between troponin and HF. Studies have 
indicated that elevated troponin concentrations in patients 
with HF are associated with more severe disease3,4 and a 
worse prognosis.5-7
Reversible injury, from myocardial strain or subendocardial 
ischemia, could lead to transient changes in cell membrane 
INTRODUCTION
The incidence of  heart failure (HF) is increasing because 
of  improved survival after myocardial infarction. It is 
important to recognize that HF is a clinical syndrome 
arising from various causes. The American Heart 
Association and European Society of  Cardiology have 
recognized the importance of  simple and reproducible 
criteria and have developed guidelines for the diagnosis of  
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Abstract
Background: Cardiac failure carries a high mortality and morbidity. Cardiac troponins and brain natriuretic peptide (BNP), are 
useful in the diagnosis and risk stratification of patients with heart failure (HF), are a better predictor of death. Both biomarkers 
are secreted directly, and almost exclusively by cardiac tissue and thought to be more sensitive than imaging or even invasive 
hemodynamics.
Objectives: The present study was done to assess the significance of troponin T and BNP levels in cardiac failure and their 
correlation with outcome.
Materials and Methods: The study included 196 patients with HF. Complete blood count, renal function test, liver function 
test, electrolytes, urine examination, electrocardiography, Chest X-ray, two-dimensional echo, cardiac troponin T, and serum 
BNP levels on admission were done for all patients. The study population was divided into 3 groups based on troponin T levels.
Results: 150 patients were in Group I with troponin T levels <0.03 ng/ml, 35 patients in Group II between 0.03 and 0.1 ng/ml, 
and Group III included 11 patients with levels more than 0.1 ng/ml. Mean duration of intensive care unit stay was 1.91 days in 
Group I, 4.03 in Group II, and 3.82 in Group III. Mean BNP values (957.3 in Group I, 2378 in Group II, and 3931.4 in Group III), 
systolic blood pressure (BP) (104 mm Hg in Group I, 96.4 in Group II, and 94 in Group III), and ejection fraction (41.92 in 
Group I, 34.18 in Group II, and 34.2 in Group III) were high in patients with higher troponin T values. All patients in group III 
required inotropic support and 45.5% patients had death.
Conclusion: An elevated cardiac troponin T values are associated with higher in-hospital mortality, lower ejection fraction and 
systolic BP, increased requirement of inotropes and prolonged intensive care.
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permeability and leakage of  cytosolic troponin. Troponin 
in cells is mostly bound to myofibrils suggesting the 
presence of  more severe injury. Troponins are released 
in response to myocyte necrosis in patients with HF.8 
Cardiac troponins and BNP are secreted directly and 
almost exclusively by cardiac tissue. They indicate 
wall stress and injury which could be more sensitive 
than imaging or invasive hemodynamics. Both the 
biomarkers are clinically significant in view of  the above 
features.
The need to counsel patients and select appropriate 
candidates for advanced therapies makes the proper 
assessment of  HF prognosis very important. Prior small 
studies have suggested that routine measurement of  cardiac 
troponins could help to identify HF patients in need of  
escalation of  therapy. High troponin T is associated with 
adverse outcomes in chronic HF especially in patients with 
lower ejection fraction.9 The role of  troponin-T and BNP 
levels are being evaluated for population-based screening 
programs and prediction of  prognosis in ambulatory CHF 
patients10,11 and in chronic kidney disease for determining 
outcome and prognosis.
The present study was aimed at evaluating the significance 
of  troponin-T levels in patients presenting with acute 
CHF in relation to diagnosis and assessment of  prognosis. 
Also we wanted to study the correlation of  troponin T 
with of  left ventricle function, in-hospital mortality, BNP, 
duration of  intensive care unit (ICU) stay, and systolic 
blood pressures (BP).
MATERIALS AND METHODS
This was a cross-sectional study of  196 patients with 
HF admitted in Sri Ramachandra Medical College and 
Hospital from the year 2008 to 2010. All patients fulfilling 
inclusion criteria (acute cardiac failure as per Framingham 
criteria) were screened and investigations done. The 
patients with age <18 years, serum creatinine more than 
2.0 mg/dl, sepsis, acute coronary syndrome, liver disease, 
and malignancy were excluded from the study. A detailed 
history was taken from all patients, and a thorough physical 
examination was done.
Framingham criteria were used for the admission diagnosis 
of  all patients - diagnosis of  CHF requires the simultaneous 
presence of  at least two major criteria or one major criterion 
in conjunction with two minor criteria. Minor criteria are 
acceptable only if  they cannot be attributed to another 
medical condition (such as pulmonary hypertension, 
chronic lung disease, cirrhosis, ascites, or nephrotic 
syndrome).
Complete blood count, renal function test, liver function 
test, electrolytes, urine examination, ECG, chest X-ray, and 
two-dimensional echo were done for all patients. Cardiac 
troponin T and serum BNP levels on admission were 
done. Cardiac troponin T was measured by the Roche 
cardiac T quantitative test which is an immunological test 
for the detection in venous blood for use with COBAS 
h 232 instrument. The study population was divided 
into three groups based on troponin T levels. Group I 
included 150 patients with troponin T levels <0.03 ng/ml, 
35 patients in Group II with levels between 0.03 and 
0.1 ng/ml, and Group III included 11 patients with levels 
more than 0.1 ng/ml.
The collected data was analyzed using the Statistical 
Package of  Social Sciences (SPSS) software. Data were 
expressed as the mean ± standard deviation. A P < 0.05 
was considered statistically significant.
RESULTS
The study included 196 patients (168 males and 28 females). 
Eight patients were in the age group of  18-40 years, 
69 patients between 41 and 60 years, and 119 patients 
above 60 years of  age.
Out of  196 patients, 76.5% patients had troponin T levels 
<0.03, 17.9% patients had troponin T levels between 0.03 
and 0.1, and 5.6% patients had troponin T levels >0.1, thus 
the majority of  patients had low troponin T levels (Table 1).
Mean duration of  ICU stay was 1.91 days in Group I, 
4.03 in Group II, and 3.82 in Group III. Mean BNP 
values (957.3 in Group I, 2378 in Group II, and 3931.4 
in Group III), systolic BP (104 mm Hg in Group I, 96.4 
in Group II, and 94 in Group III), and ejection fraction 
(41.92 in Group I, 34.18 in Group II, and 34.2 in Group III) 
were high in patients with higher troponin T values. All 
patients in Group III required inotropic support and 45.5% 
patients had death. All were statistically significant except 
for systolic BP (Table 2).
DISCUSSION
Troponin T values on admission correlate well with 
morbidity and mortality. Out of  196 patients, 76.5% patients 
Table 1: The study group
Groups Troponin T Frequency Percentage
I <0.03 150 76.5
II 0.03-0.1 35 17.9
III >0.1 11 5.6
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had troponin T levels <0.03, 17.9% patients had troponin T 
levels between 0.03 and 0.1, and 5.6% patients had troponin 
T levels>0.1, thus the majority of  patients had low troponin 
T levels. In a study by Peacock et al.,12 Troponin was measured 
at the time of  admission in 84,872 of  105,388 patients 
(80.5%) who were hospitalized for acute decompensated 
HF. Of  these patients, 67,924 had a creatinine level of  
<2.0 mg per deciliter. Cardiac troponin I was measured in 
61,379 patients, and cardiac troponin T in 7880 patients 
(both proteins were measured in 1335 patients). Overall, 
4240 patients (6.2%) were positive for troponin. Thus, the 
frequency correlated well with the present study.
The mean duration of  ICU stay was lower (1.91 days) in 
patients with low troponin T value (<0.03 ng/ml), and was 
highest (4.03 days), for the patient group whose troponin 
T were between 0.03 and 0.1 ng/ml. The mean duration 
for ICU care for patients with troponin T above 0.1 ng/ml 
was 3.82 days. The lower value of  mean for the patient 
group with troponin T above 0.1 ng/ml was 3.82 days can 
explained by the fact that early deaths in this subgroup 
resulted in shorter ICU stay compared to the patients group 
whose troponin T were between 0.03 and 0.1 ng/ml. In the 
study done by Peacock et al., the median ICU stay was 4.1 
for patients who were positive for troponin and 3.7 who 
were negative for troponin.
In the present study, patients with high troponin levels 
(>0.1 ng/m) had low mean systolic pressures of  94 mm Hg 
and patients with low troponin levels (<0.03 ng/ml) had 
higher mean systolic pressures of  103.9 mm Hg. Thus, 
patients with higher troponin T values were associated 
with lower systolic pressures and the results correlated 
well with the above studies. In the study done by Peacock 
et al., patients with high troponin had lower systolic BP 
on admission, than those who had normal troponin. In 
one small study by Koide et al.,13 there was no significant 
differences of  BP between the two groups. In another small 
study by Angheloiu et al.,14 systolic BP correlated well with 
troponin levels.
We measured serum troponin T, plasma BNP, and left 
ventricular ejection fraction (LVEF) on admission. In the 
present study, the mean BNP for patients with troponin T 
values <0.01 ng/ml was 967.53 and for the patients with 
troponin T values above 0.1 ng/ml was 3934.94. The mean 
BNP rise is proportional to an elevation of  troponin T 
values. We hypothesize that an increase in troponin T 
concentrations is an expression of  ongoing myocyte injury 
unmitigated by treatment of  CHF and associated with a 
greater rise in BNP concentrations. Similar observations 
were in a study by Sato et al. In a small study by Koide et al., 
patients in high troponin T group were significantly older 
and had a higher BNP on admission, as well as a higher 
prevalence of  diabetes, and worse NYHA functional class 
at discharge. They also had higher discharge levels of  BNP.
The measurement of  troponin levels in patients who 
present with HF could provide independent prognostic 
information regarding in-hospital death and other clinical 
outcomes and can be useful for risk stratification of  such 
patients. Ishii et al. reported a weak correlation between 
troponin T and BNP concentrations and suggested that 
markers specific for ongoing myocardial damage and 
left ventricular overload reflect different aspects of  the 
pathophysiology of  CHF and may identify different groups 
of  patients at risk.
In the present study, the ejection fraction was highest (41.92) 
for patients with troponin <0.03 ng/ml and lower (34.18) 
for patients with troponin T value more than 0.1 ng/ml, 
elevated levels were associated with decline in LVEF and 
higher mortality rates. Increased wall stress and myocyte 
death may explain the mechanisms. Increased wall stress 
may directly activate intracellular signaling cascades and 
decreased subendocardial perfusion even in the absence 
of  coronary artery disease, resulting in a decline in systolic 
function. In the study done by Peacock et al., patients with 
high troponin had lower ejection fraction on admission.
In the present study, 45.5% of  patients died in the subgroup 
of  patients with higher troponin T (more than 0.1 ng/ml) 
and 20% of  died in subgroup of  patients with troponin T 
(0.03-0.1 ng/ml), whereas only 3.1% deaths were observed 
in patients with low troponin T (<0.03 ng/ml). Mortality 
was higher as the troponin T value increased. As per 
the available literature, persistently elevated levels were 
associated with a decline in LVEF and higher mortality 
rates. Additional factors, including activation of  the renin-
angiotensin system, sympathetic nervous system, and 
inflammatory cytokine system, have been implicated in 
provoking myocyte injury and cell death in HF.
The strength of  the study is that we had observed a 
reasonable number to have a specific conclusion, but the 
Table 2: Clinical and lab parameters with outcome
Parameter Group I Group II Group III P value
Systolic BP - Mean 
value (mm Hg)
104 96.4 94 0.319
Inotropic support - Oral (N) 90 4 0 0.001
Inotropic support - 
Intravenous (N)
23 27 11 0.001
Ejection fraction - 
Mean value (%)
41.92 34.18 34.2 0.001
BNP mean value (pg/ml) 967.53 2378 3934.94 0.001
ICU stay 
(mean duration days)
1.91 4.03 3.82 0.001
Death (N) 2 7 5 0.001
BP: Blood pressure, BNP: Brain natriuretic peptide, ICU: Intensive care unit
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limitations remain. Our study differs from most of  the 
prospective design by other studies and targeted focus on 
hospitalized patients. We did not do serial monitoring of  
troponin T and BNP levels and could not determine the 
persistence or variability of  troponin T and BNP elevations 
during hospital stay. Furthermore, we could not do other 
available markers of  cardiac failure.
CONCLUSION
There is an association between elevated cardiac troponin 
levels and adverse events in hospitalized patients 
with acute decompensated HF. In patients with acute 
decompensated HF, an elevated cardiac troponin T values 
are associated with higher in-hospital mortality, lower 
ejection fraction and systolic BP, increased requirement 
of  inotropes, and need for prolonged intensive care. 
The combination of  measuring cardiac troponin levels, 
a marker for ongoing myocardial damage, and BNP, a 
marker for left ventricular overload, represents a highly 
effective means of  risk stratification of  patients with acute 
decompensated HF.
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